Literature DB >> 30055855

Non-vascularised fibular bone graft after vascular crisis: compensation for the failure of vascularised fibular free flaps.

N Xiao1, L Zhang2, X Peng1, C Mao1, J Zhang1, Z G Cai1.   

Abstract

After reconstruction of a segmental mandibular defect with a fibular free flap, a vascular crisis can be detected clinically and a "no-flow" phenomenon found during re-exploration. Traditional methods used to solve this include removal of the failed flap and delayed mandibular reconstruction, or restoration of the defect with a functional reconstruction plate or contralateral fibular free flap. Our aim therefore was to investigate under what circumstances it is feasible to use a non-vascularised fibular bone graft (NVFB) as a free bone graft after the failure of a vascularised fibular free flap. From 1 January 2010-31 December 2014, 10 patients who had NVFB after failure of a fibular free flap were included in the study. All patients were treated at the Peking University School and Hospital of Stomatology. NVFB were preserved successfully without infection in all 10 cases, and follow-up imaging showed that it had incorporated well with the residual mandible, the basic function and facial aesthetics of which were maintained. In conclusion we have identified that by precise selection of patients, detailed preoperative planning, and meticulous postoperative care, NVFB can be used as a "rescue" technique after failure of a fibular free flap, and can successfully restore the segmental mandibular defect and facial contour.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Fibular free flap; Non-vascularised bone graft; Vascular crisis

Mesh:

Year:  2018        PMID: 30055855     DOI: 10.1016/j.bjoms.2018.06.018

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  1 in total

1.  Jaw reconstruction with vascularized fibular flap: The 11-year experience among 104 patients.

Authors:  Shengjie Shao; Weihong Wang; Biao Xu; Yu Liu; Zhe Zhang
Journal:  World J Surg Oncol       Date:  2020-02-29       Impact factor: 2.754

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.